- Home
- PETS vs SCYX Comparison
PETS vs SCYX Comparison
Compare PETS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | SCYX |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 26.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PETS | SCYX |
|---|---|---|
| Price | $3.22 | $0.61 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.20 | $3.00 |
| AVG Volume (30 Days) | ★ 7.7M | 388.0K |
| Earning Date | 02-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $198,265,000.00 | $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | $2.98 | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.57 |
| 52 Week High | $5.58 | $1.49 |
Technical Indicators
Market Signals| Indicator | PETS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | 42.42 |
| Support Level | $3.36 | $0.58 |
| Resistance Level | $3.64 | $0.64 |
| Average True Range (ATR) | 0.41 | 0.03 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 64.26 | 36.15 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.